These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35107895)

  • 1. [Pharmacovigilance - mRNA COVID-19 vaccines : current state of knowledge on their adverse effects].
    Favre V; Ekobena P; Chtioui H; Rothuizen LE; Livio F; Genton B; Buclin T
    Rev Med Suisse; 2022 Feb; 18(767):190-197. PubMed ID: 35107895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacovigilance signals from active surveillance of mRNA platform vaccines (tozinameran and elasomeran).
    Valnet-Rabier MB; Tebacher M; Gautier S; Micallef J; Salvo F; Pariente A; Bagheri H
    Therapie; 2023; 78(5):499-507. PubMed ID: 37012149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and Associations of Adverse Reactions of COVID-19 Vaccines Reported to Pharmacovigilance Systems in the European Union and the United States.
    Montano D
    Front Public Health; 2021; 9():756633. PubMed ID: 35186864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety of mRNA COVID-19 vaccines to influenza vaccines: A pharmacovigilance analysis using WHO international database.
    Kim MS; Jung SY; Ahn JG; Park SJ; Shoenfeld Y; Kronbichler A; Koyanagi A; Dragioti E; Tizaoui K; Hong SH; Jacob L; Salem JE; Yon DK; Lee SW; Ogino S; Kim H; Kim JH; Excler JL; Marks F; Clemens JD; Eisenhut M; Barnett Y; Butler L; Ilie CP; Shin EC; Il Shin J; Smith L
    J Med Virol; 2022 Mar; 94(3):1085-1095. PubMed ID: 34709664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge.
    Lacroix C; Salvo F; Gras-Champel V; Gautier S; Massy N; Valnet-Rabier MB; Grandvuillemin A; Mounier C; Benkebil M; Pariente A; Jonville-Béra AP; Micallef J;
    Therapie; 2021; 76(4):297-303. PubMed ID: 34059351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A trial platform to assess approved SARS-CoV-2 vaccines in immunocompromised patients: first sub-protocol for a pilot trial comparing the mRNA vaccines Comirnaty® and COVID-19 mRNA Vaccine Moderna®.
    Speich B; Chammartin F; Smith D; Stoeckle MP; Amico P; Eichenberger AL; Hasse B; Schuurmans MM; Müller T; Tamm M; Dickenmann M; Abela IA; Trkola A; Hirsch HH; Manuel O; Cavassini M; Hemkens LG; Briel M; Mueller NJ; Rauch A; Günthard HF; Koller MT; Bucher HC; Kusejko K;
    Trials; 2021 Oct; 22(1):724. PubMed ID: 34674742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
    Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2022; 29(1):4-18. PubMed ID: 34355678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of acute necrotising pancreatitis following the second dose of Pfizer-BioNTech COVID-19 mRNA vaccine.
    Walter T; Connor S; Stedman C; Doogue M
    Br J Clin Pharmacol; 2022 Mar; 88(3):1385-1386. PubMed ID: 34423463
    [No Abstract]   [Full Text] [Related]  

  • 13. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported reactogenicity of CoronaVac (Sinovac) compared with Comirnaty (Pfizer-BioNTech): A prospective cohort study with intensive monitoring.
    Lai FTT; Leung MTY; Chan EWW; Huang L; Lau LKW; Peng K; Leung JCN; Fan M; Chen K; Lum DH; Li X; Chui CSL; Wan EYF; Wong CKH; Lam EFS; Cheung TYY; Cowling BJ; Wong ICK; Chan EWY
    Vaccine; 2022 Mar; 40(10):1390-1396. PubMed ID: 35140013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Safety of COVID-19 Vaccines: A Primer.
    Petousis-Harris H
    Drug Saf; 2020 Dec; 43(12):1205-1210. PubMed ID: 32997318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
    Sagili Anthony DP; Sivakumar K; Venugopal P; Sriram DK; George M
    Clin Drug Investig; 2021 Jun; 41(6):499-509. PubMed ID: 33754328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In brief: Myocarditis with the Pfizer/BioNTech and Moderna COVID-19 vaccines.
    Med Lett Drugs Ther; 2021 Jul; 63(1629):e9. PubMed ID: 34544112
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute myocarditis following Comirnaty vaccination in a healthy man with previous SARS-CoV-2 infection.
    Patrignani A; Schicchi N; Calcagnoli F; Falchetti E; Ciampani N; Argalia G; Mariani A
    Radiol Case Rep; 2021 Nov; 16(11):3321-3325. PubMed ID: 34367386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
    Nojszewska M; Kalinowska A; Adamczyk-Sowa M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(1):8-11. PubMed ID: 33555604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed Cutaneous Hypersensitivity Reaction to Vaxzevria (ChAdOx1-S) Vaccine against SARS-CoV-2.
    Sprute R; Schumacher S; Pauls M; Pauls W; Cornely OA
    Drugs R D; 2021 Dec; 21(4):371-374. PubMed ID: 34351606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.